Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.130
+0.070 (3.40%)
Sep 4, 2025, 9:46 AM - Market open
Daré Bioscience Stock Forecast
Stock Price Forecast
The 2 analysts that cover Daré Bioscience stock have a consensus rating of "Strong Buy" and an average price target of $10, which forecasts a 369.48% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $12.
Price Target: $10 (+369.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Daré Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $8 | Hold → Strong Buy | Upgrades | $8 | +275.59% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +463.38% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +463.38% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +463.38% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +463.38% | Oct 24, 2024 |
Financial Forecast
Revenue This Year
7.33M
from 9.78K
Increased by 74,787.57%
Revenue Next Year
17.71M
from 7.33M
Increased by 141.76%
EPS This Year
-2.02
from -0.48
EPS Next Year
-0.83
from -2.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.7M | 44.2M | |||
| Avg | 7.3M | 17.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 272,774.1% | 503.3% | |||
| Avg | 74,787.6% | 141.8% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.56 | 1.37 | |||
| Avg | -2.02 | -0.83 | |||
| Low | -3.01 | -3.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.